4 / 9
Page 29
Notes:
3
rd
International Conference on
Health Care and
Health Management
Joint Event
&
November 04-05, 2019 | Prague, Czech Republic
6
th
International Conference on
Neuroscience and
Neurological Disorders
Journal of Public Health Policy and Planning | Volume 3
Glucose toxicity: The worldwide problem and the all-natural solution
John F Burd
Lysulin Inc, USA
G
lucose toxicity is aworldwide epidemic leading to the
insulin resistance and the development of obesity and
Type2diabetes inboth childrenandadults. Inaddition topoor
health and early death, this is costing our healthcare systems
a fortune to treat diabetes and its complications. Glucose is
not a passive bystander in our bloodstream but is a toxic and
reactive compound. Glucose reacts with all of the proteins in
our body forming glycated proteins. These glycated proteins
progress to become what is known as Advanced Glycation
Endproducts (AGEs). These AGEs are known to be the culprits
associated with kidney failure, blindness, amputations and
cardiovasular disease. Protein glycation is also the cause of
insulin resistance which can lead to insulin depletion. When
this happens, we have to resort to injection of insulin in an
attempt to keep our blood glucose levels in the normal range.
In over 20 years of R&D and clinical studies, nutritional
supplements have been proven to combat glucose toxicity.
Three important supplements having this ability are LYSINE,
ZINC and VITAMIN C. These three supplements are now in
one tablet, Lysulin® to combat glucose toxicity and protein
glycation. Unlike the available prescription drugs for type
2 diabetes which are directed at the symptoms of diabetes
(high blood glucose), Lysulin is directed at the problem, which
is protein glycation. Clinical studies have proven that Lysulin
supplementation lowers HbA1c better thanmost prescription
drugs for diabetes. Historically, supplements have had a bad
reputationbecausemanyofthemhavemadeunsubstantiated
claims. Conversely, Lysulin is firmly grounded on a foundation
published literature and clinical studies proving that Lysulin
will lower blood glucose and glycated proteins. The history of
studies proving the effectiveness of Lysulin will be presented
along with recent data from double blind placebo controlled
studies.
Speaker Biography
John F Burd is a Founder & CEO of Lysulin, Inc, and has launched an all-
natural, scientifically proven nutraceutical product proven to improve
the health of people with diabetes. He also found Wonder Spray, llc.,
making a natural antibiotic soution useful for a variety of ailments that
kills all pathogens and yet is safe and non-toxic to human tissues. Prior
to Lysulin, He was a General Partner of Windamere Venture Partners. He
was previously President & CEO of DexCom, now the leader in continuing
glucose monitoring for people with diabetes. He has authored over 50
publications and holds 35 patents. He graduated from Purdue University
with a B.S. in Biochemistry, and earned an M.S. and Ph.D., from the
University of Wisconsin. In 2010 he was inducted into the American
Association of Clinical Chemistry Hall of Fame and received the Ullman
Prize for innovation in clinical chemistry.
e:
jburd@jburd.com